Monoclonal Antibody to Lectin Like Oxidized Low Density Lipoprotein Receptor 1 (LOX1)
| Code | Size | Price |
|---|
| MAB859Hu22-20ul | 20ul | £87.00 |
Quantity:
| MAB859Hu22-100ul | 100ul | £162.00 |
Quantity:
| MAB859Hu22-200ul | 200ul | £219.00 |
Quantity:
| MAB859Hu22-1ml | 1ml | £502.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
OLR1; CLEC8A; SCARE1; Oxidized low-density lipoprotein receptor 1; C-type lectin domain family 8 member A; Lectin-like oxidized LDL receptor 1; Lectin-type oxidized LDL receptor 1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Lectin Like Oxidized Low Density Lipoprotein Receptor 1
Potency (Clone Number):
C9
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL<br/>Immunohistochemistry: 5-20ug/mL<br/>Immunocytochemistry: 5-20ug/mL<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Lectin Like Oxidized Low Density Lipoprotein Receptor 1 (LOX1) | RPB859Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||